Focus: Galderma is a specialty dermatology company headquartered in Dallas focused on dermatological consumer products and drugs across rosacea, acne, psoriasis, and aesthetic medicine. The company generates significant revenue from its mature dermatology franchise with products spanning topical treatments, injectables, and medical devices.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Galderma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Galderma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Galderma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Revenue-generating anchor but facing patent expiry in ~3 years with no disclosed replacement revenue source, representing primary revenue cliff risk.
Stable rosacea therapeutic with extended patent protection through 2034; represents core franchise product with growth potential in expanding aesthetic dermatology market.
Novel retinoid agonist (RAR-gamma selective) addressing acne with Phase 4 trials ongoing; represents newer generation product with 10-year patent runway and potential for market share gains.
Vitamin D analog addressing psoriasis with multiple pipeline expansions; faces generic competition risk but maintaining steady revenue base.
Alpha-2 agonist for rosacea erythema with Phase 3 expansion into capillary malformations; solid patent protection and pipeline activity supporting continued relevance.
24 discontinued, 38 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No recent WARN Act filings or FDA warning letters suggest regulatory and employment stability; metronidazole injection shortage is supply-side (not company-specific) and unlikely to impact career trajectory.
+3 more products